<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04937387</url>
  </required_header>
  <id_info>
    <org_study_id>214263</org_study_id>
    <nct_id>NCT04937387</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled Asthma</brief_title>
  <official_title>A Phase III, 12 Week, Randomized, Double-blind, 4 Arm Parallel Group Bridging Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination FF/UMEC/VI Once-daily Via a Dry Powder Inhaler With Dual Combination of FF/VI, Administered in Chinese Participants With Inadequately Controlled Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to evaluate the efficacy, safety and tolerability of FF/UMEC/VI compared with&#xD;
      FF/VI via ELLIPTAÂ® inhaler in Chinese participants with inadequately controlled asthma.&#xD;
      ELLIPTA is a registered trademark of GlaxoSmithKline group of companies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 29, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cohorts 1 and 2: Change from Baseline in trough Forced expiratory volume in 1 second (FEV1) (Liters)</measure>
    <time_frame>Baseline and at Week 12</time_frame>
    <description>FEV1 will be measured using spirometry.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cohort 3 and 4: Change from Baseline in trough FEV1 (Liters)</measure>
    <time_frame>Baseline and at Week 12</time_frame>
    <description>FEV1 will be measured using spirometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohorts 1, 2 , 3 and 4: Change from Baseline in Asthma Control Questionnaire (7 items) (ACQ-7) (Scores on a scale)</measure>
    <time_frame>Baseline and at Week 12</time_frame>
    <description>ACQ-7 is a questionnaire used to assess the asthma control. Six attributes are measured with a participant-completed questionnaire assessing nocturnal awakening, waking in the morning, activity limitation, shortness of breath, wheeze and rescue medication use and the seventh attribute measures lung function. A score of less than or equal to (&lt;=)0.75 indicates well-controlled asthma and a score greater than or equal to (&gt;=)1.5 indicates poorly controlled asthma. A change of 0.5 in score suggests a clinically important change in score. Higher score indicates poor asthma control and lower score indicates well-controlled asthma.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">356</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Participants receiving FF/VI at Dose level 1 via ELLIPTA inhaler</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Participants receiving FF/UMEC/VI at Dose level 2 via ELLIPTA inhaler</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Participants receiving FF/ VI at Dose level 3 via ELLIPTA inhaler</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: Participants receiving FF/UMEC/VI at Dose level 4 via ELLIPTA inhaler</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FF/VI</intervention_name>
    <description>FF/VI will be administered.</description>
    <arm_group_label>Cohort 1: Participants receiving FF/VI at Dose level 1 via ELLIPTA inhaler</arm_group_label>
    <arm_group_label>Cohort 3: Participants receiving FF/ VI at Dose level 3 via ELLIPTA inhaler</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FF/UMEC/VI</intervention_name>
    <description>FF/UMEC/VI will be administered.</description>
    <arm_group_label>Cohort 2: Participants receiving FF/UMEC/VI at Dose level 2 via ELLIPTA inhaler</arm_group_label>
    <arm_group_label>Cohort 4: Participants receiving FF/UMEC/VI at Dose level 4 via ELLIPTA inhaler</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ELLIPTA</intervention_name>
    <description>FF/UMEC/VI and FF/VI will be administered via ELLIPTA inhaler.</description>
    <arm_group_label>Cohort 1: Participants receiving FF/VI at Dose level 1 via ELLIPTA inhaler</arm_group_label>
    <arm_group_label>Cohort 2: Participants receiving FF/UMEC/VI at Dose level 2 via ELLIPTA inhaler</arm_group_label>
    <arm_group_label>Cohort 3: Participants receiving FF/ VI at Dose level 3 via ELLIPTA inhaler</arm_group_label>
    <arm_group_label>Cohort 4: Participants receiving FF/UMEC/VI at Dose level 4 via ELLIPTA inhaler</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Participant must be 18 years or older at the time of signing the informed consent.&#xD;
&#xD;
          -  Documented history asthma diagnosis as defined by the Global Initiative for Asthma&#xD;
             (GINA) at least one year prior to Visit 0.&#xD;
&#xD;
          -  Participants with inadequately controlled asthma (ACQ-6 score &gt;=1.5) despite Inhaled&#xD;
             Corticosteroids/Long-Acting Beta-2-Agonists (ICS/LABA) maintenance therapy at Visit 1.&#xD;
&#xD;
          -  Participants who require daily ICS/LABA for at least 12 weeks prior to Visit 0 with no&#xD;
             changes to maintenance asthma medications during the 6 weeks immediately prior to&#xD;
             Visit 0 (including no changes to a stable total dose of ICS of greater than [&gt;]250&#xD;
             micrograms (mcg) per day fluticasone propionate [FP, or equivalent]).&#xD;
&#xD;
          -  A best pre-bronchodilator morning (AM) FEV1 &gt;=30 percent (%) and less than (&lt;) 85% of&#xD;
             the predicted normal value at Visit 1. Predicted values will be based upon the&#xD;
             European Respiratory Society (ERS) Global Lung Function Initiative.&#xD;
&#xD;
          -  Airway reversibility defined as &gt;=12% and &gt;=200 milliliters (mL) increase in FEV1&#xD;
             between 20 and 60 minutes following 4 inhalations of albuterol/salbutamol aerosol at&#xD;
             Visit 1.&#xD;
&#xD;
          -  All participants must be able to replace their current Short-Acting Beta-2-Agonists&#xD;
             (SABA) inhaler with albuterol/salbutamol aerosol inhaler at Visit 1 as needed for the&#xD;
             duration of the study. Participants must be judged capable of withholding&#xD;
             albuterol/salbutamol for at least 6 hours prior to study visits.&#xD;
&#xD;
          -  Male or female participants following contraceptive/barrier requirements and it should&#xD;
             be consistent with local regulations regarding the methods of contraception for those&#xD;
             participating in clinical studies. A female participant is eligible to participate if&#xD;
             she is not pregnant or breastfeeding, and one of the following conditions applies: Is&#xD;
             a woman of non-childbearing potential (WONCBP) or a woman of childbearing potential&#xD;
             (WOCBP) who agrees to follow the contraceptive guidance during the study.&#xD;
&#xD;
          -  Capable of giving signed informed consent which includes compliance with the&#xD;
             requirements and restrictions listed in the informed consent form (ICF) and in this&#xD;
             protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chest X-ray documented pneumonia in the 6 weeks prior to Visit 1.&#xD;
&#xD;
          -  Any asthma exacerbation requiring a change in maintenance asthma therapy in the 6&#xD;
             weeks prior to Visit 1.&#xD;
&#xD;
          -  Participants with the diagnosis of chronic obstructive pulmonary disease, as per&#xD;
             Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, including&#xD;
             all of the following:&#xD;
&#xD;
               1. History of exposure to risk factors (especially tobacco smoke, occupational dusts&#xD;
                  and chemicals, smoke from home cooking and heating fuels).&#xD;
&#xD;
               2. A post-albuterol/salbutamol FEV1/Forced Vital Capacity (FVC) ratio of &lt;0.70 and a&#xD;
                  post-albuterol/salbutamol FEV1 of less than or equal to (&lt;=)70% of predicted&#xD;
                  normal values.&#xD;
&#xD;
               3. Onset of disease &gt;=40 years of age.&#xD;
&#xD;
          -  Participants with current evidence of pneumonia, active tuberculosis, lung cancer,&#xD;
             significant bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension,&#xD;
             interstitial lung diseases or other active pulmonary diseases or abnormalities other&#xD;
             than asthma.&#xD;
&#xD;
          -  Immune suppression (e.g., Human Immunodeficiency virus [HIV], Lupus) or other risk&#xD;
             factors for pneumonia (e.g., neurological disorders affecting control of the upper&#xD;
             airway, such as Parkinson's Disease, Myasthenia Gravis). Participants at potentially&#xD;
             high risk (e.g., very low Body Mass Index [BMI], severely malnourished, or very low&#xD;
             FEV1) will only be included at the discretion of the Investigator.&#xD;
&#xD;
          -  Participants with historical or current evidence of clinically significant&#xD;
             cardiovascular, neurological, psychiatric, renal, hepatic, immunological,&#xD;
             gastrointestinal, urogenital, nervous system, musculoskeletal, skin, sensory,&#xD;
             endocrine (including uncontrolled diabetes or thyroid disease) or hematological&#xD;
             abnormalities that are uncontrolled. Significant is defined as any disease that, in&#xD;
             the opinion of the Investigator, would put the safety of the participant at risk&#xD;
             through participation, or which would affect the efficacy or safety analysis if the&#xD;
             disease/condition exacerbated during the study.&#xD;
&#xD;
          -  Unstable liver disease as defined by the presence of ascites, encephalopathy,&#xD;
             coagulopathy, hypoalbuminaemia, esophageal or gastric varices or persistent jaundice,&#xD;
             cirrhosis, known biliary abnormalities (with the exception of Gilbert's syndrome or&#xD;
             asymptomatic gallstones).&#xD;
&#xD;
          -  Clinically significant Electrocardiogram (ECG) abnormality: Evidence of a clinically&#xD;
             significant abnormality in the 12-lead ECG performed during screening. The&#xD;
             Investigator will determine the clinical significance of each abnormal ECG finding in&#xD;
             relation to the participant's medical history and exclude participants who would be at&#xD;
             undue risk by participating in the trial. An abnormal and clinically significant&#xD;
             finding is defined as a 12-lead tracing that is interpreted as, but not limited to,&#xD;
             any of the following:&#xD;
&#xD;
               1. Atrial Fibrillation with rapid ventricular rate &gt;120 beats per minute (bpm).&#xD;
&#xD;
               2. Sustained or non-sustained ventricular tachycardia.&#xD;
&#xD;
               3. Second degree heart block Mobitz type II and third degree heart block (unless&#xD;
                  pacemaker or defibrillator had been inserted).&#xD;
&#xD;
               4. QT interval corrected for heart rate by Fridericia's formula (QTcF) &gt;=500&#xD;
                  milliseconds (msec) in participants with QRS &lt;120 msec and QTcF &gt;=530 msec in&#xD;
                  participants with QRS &gt;=120 msec.&#xD;
&#xD;
          -  Participants with any of the following at Screening (Visit 1):&#xD;
&#xD;
               1. Myocardial infarction or unstable angina in the last 6 months.&#xD;
&#xD;
               2. Unstable or life-threatening cardiac arrhythmia requiring intervention in the&#xD;
                  last 3 months.&#xD;
&#xD;
               3. New York Heart Association (NYHA) Class IV Heart failure [American Heart&#xD;
                  Association, 2016].&#xD;
&#xD;
          -  Participants with a medical condition such as narrow-angle glaucoma, urinary&#xD;
             retention, prostatic hypertrophy or bladder neck obstruction should only be included&#xD;
             if in the opinion of the Investigator the benefit outweighs the risk and that the&#xD;
             condition would not contraindicate study participation.&#xD;
&#xD;
          -  Participants with carcinoma that has not been in complete remission for at least 5&#xD;
             years. Participants who have had carcinoma in situ of the cervix, squamous cell&#xD;
             carcinoma and basal cell carcinoma of the skin would not be excluded based on the 5&#xD;
             year waiting period if the participant has been considered cured by treatment.&#xD;
&#xD;
          -  Participants with a history of psychiatric disease, intellectual deficiency, poor&#xD;
             motivation or other conditions that will limit the validity of informed consent to&#xD;
             participate in the study.&#xD;
&#xD;
          -  Participants who are medically unable to withhold their albuterol/salbutamol for the&#xD;
             6-hour period required prior to spirometry testing at each study visit.&#xD;
&#xD;
          -  Participants who are:&#xD;
&#xD;
               1. Current smokers (defined as participants who have used inhaled tobacco products&#xD;
                  within the 12 months prior to Visit 1, e.g. cigarettes,&#xD;
                  electronic-cigarettes/vaping, cigars or pipe tobacco).&#xD;
&#xD;
               2. Former smokers with a smoking history of &gt;=10 pack years (e.g. &gt;=20 cigarettes&#xD;
                  per day for 10 years).&#xD;
&#xD;
          -  Participants with a known or suspected history of alcohol or drug abuse within the&#xD;
             last 2 years.&#xD;
&#xD;
          -  A history of allergy or hypersensitivity to any corticosteroid,&#xD;
             anticholinergic/muscarinic receptor antagonist, beta2-agonist, lactose/milk protein or&#xD;
             magnesium stearate.&#xD;
&#xD;
          -  Participants at risk of non-compliance, or unable to comply with the study procedures.&#xD;
             Any infirmity, disability, or geographic location that would limit compliance for&#xD;
             scheduled visits.&#xD;
&#xD;
          -  Study Investigators, sub-Investigators, study coordinators, employees of a&#xD;
             participating Investigator or study site, or immediate family members of the&#xD;
             aforementioned that is involved with this study.&#xD;
&#xD;
          -  In the opinion of the Investigator, any participant who is unable to read and/or would&#xD;
             not be able to complete study related materials.&#xD;
&#xD;
        Inclusion criteria for randomization:&#xD;
&#xD;
          -  Participants with inadequately controlled asthma (ACQ-6 score &gt;=1.5) at Visit 2.&#xD;
&#xD;
          -  A best pre-bronchodilator morning (AM) FEV1 &gt;=30% and &lt;90% of the predicted normal&#xD;
             value at Visit 2. Predicted values will be based upon the ERS Global Lung Function&#xD;
             Initiative (Quanjer).&#xD;
&#xD;
          -  Liver function tests at Visit 1:&#xD;
&#xD;
               1. Alanine aminotransferase (ALT) &lt;2 times upper limit of normal (ULN).&#xD;
&#xD;
               2. Alkaline phosphatase &lt;=1.5 times ULN.&#xD;
&#xD;
               3. Bilirubin &lt;=1.5 times ULN (isolated bilirubin &gt;1.5 times ULN is acceptable if&#xD;
                  bilirubin is fractionated and direct bilirubin &lt;35%).&#xD;
&#xD;
          -  Compliance with completion of the Electronic diary reporting defined as completion of&#xD;
             all questions/assessment on &gt;=4 of the last 7 days during the run-in period.&#xD;
&#xD;
        Exclusion criteria for randomization:&#xD;
&#xD;
          -  Occurrence of a culture-documented or suspected bacterial or viral infection of the&#xD;
             upper or lower respiratory tract, sinus or middle ear during the run-in period that&#xD;
             led to a change in asthma management or, in the opinion of the Investigator, is&#xD;
             expected to affect the participant's asthma status or the participant's ability to&#xD;
             participate in the study.&#xD;
&#xD;
          -  Evidence of a severe exacerbation during screening or the run-in period, defined as&#xD;
             deterioration of asthma requiring the use of systemic corticosteroids (tablets,&#xD;
             suspension, or injection) for at least 3 days or an in-patient hospitalization or&#xD;
             emergency department visit due to asthma that required systemic corticosteroids.&#xD;
&#xD;
          -  Changes in asthma medication (excluding run-in medication and albuterol/salbutamol&#xD;
             inhalation aerosol provided at Visit 1).&#xD;
&#xD;
          -  Evidence of clinically significant abnormal laboratory tests during screening or&#xD;
             run-in which are still abnormal upon repeat analysis and are not believed to be due to&#xD;
             disease(s) present. Each Investigator will use his/her own discretion in determining&#xD;
             the clinical significance of the abnormality.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US GSK Clinical Trials Call Center</last_name>
    <phone>877-379-3718</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>EU GSK Clinical Trials Call Center</last_name>
    <phone>+44 (0) 20 89904466</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jiangmen</city>
        <state>Guangdong</state>
        <zip>529030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yanming Huang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Qingyuan</city>
        <state>Guangdong</state>
        <zip>510030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Dongbo Guangdong Tian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Zhanjiang</city>
        <state>Guangdong</state>
        <zip>524001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Bin Wu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Haikou</city>
        <state>Hainan</state>
        <zip>570311</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Xingjun Cai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <zip>214023</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Tao Bian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266071</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Wei Han</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hangzhou</city>
        <zip>310005</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sheng Huang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hangzhou</city>
        <zip>310006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Limin Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tianjin</city>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jie Cao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Zhengzhou</city>
        <zip>450000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Limin Zhao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 2, 2021</study_first_submitted>
  <study_first_submitted_qc>June 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)</keyword>
  <keyword>Fluticasone Furoate/Vilanterol (FF/VI)</keyword>
  <keyword>ELLIPTA</keyword>
  <keyword>Chinese</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>http://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

